Effects of almitrine-raubasine on learning-memory ability in chronic episodic hypoxia rat and possible biochemical mechanism involved / 中华神经科杂志

Objective To investigate the effects of almitrine-raubasine on learning-memory ability and brain choline acetyltransferase (ChAT) activity in chronic episodic hypoxia (EHYP) rat. Methods After establishing the rat model of EHYP, almitrine-raubasine (0.03 tablets/250 g body weight , Bid) was given to the EHYP rats. The learning-memory ability was evaluated by using passive avoidance test and the ChAT activity in three different brain regions (including cerebral cortex, hippocampus and striatum) was determined using radiochemical method. Results As compared with the controlled rats, the performance on passive avoidance test of EHYP rats was impaired significantly (P

Effects of almitrine and raubasine on rehabilitation of ischemic stroke patient / 中华神经科杂志

Objective To assess the efficacy of almitrine and raubasine (Duxil) on post stroke rehabilitation Methods A clinical trial was done with a randomized, double blind, placebo controlled method Patients with ischemic stroke were included as having 1 month after the acute onset and receiving randomized treatment of either Duxil or placebo 2 tablets daily for 3 months The patients were assessed by using Barthel Index (BI), neurological functional deficit scores (NFDS), and Hasagawa dementia scales (HDS) each month after giving treatment Results In this study, only 74 cases were observed Of them, 38 patients received Duxil and 36 patients received placebo The baseline characteristics were compared between both groups Duxil was significantly shown more effective than placebo by increasing BI at 1, 2 or 3 months and by reducing NFDS at 1 month after treatment, more Duxil treated patients' NFDS had improved as compared with placebo treated patients In comparing with the pre treatment condition, there appeared a strong tendency of improvement in HDS with Duxil, although this significance was not confirmed by the difference of scores between two groups More Duxil treated patients than placebo controlled patients were reported having adverse events, but the difference was not significant at the 5% level All these events were mild, of short duration and resolved without treatment Conclusion Duxil can accelerate the recovery of nervous function to some degrees after stroke